SOURCE: Corcept Therapeutics

Corcept Therapeutics

March 05, 2015 08:00 ET

Corcept Therapeutics Announces Nine Poster Presentations on Mifepristone for the Treatment of Cushing's Syndrome at the 97th Annual Endocrine Society Meeting

MENLO PARK, CA--(Marketwired - Mar 5, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that a variety of posters about Korlym® (mifepristone) will be presented at the 97th annual Endocrine Society Meeting (ENDO 2015) being held at the San Diego Convention Center from March 5 - 7, 2015.

"We are pleased to see the breadth of new data being presented at ENDO 2015 about Korlym (mifepristone), which adds to the already substantial literature describing the use of mifepristone to treat Cushing's Syndrome," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "We are committed to bringing innovative therapies to patients in need, and we look forward to continuing our pivotal role in advancing the scientific understanding of Cushing's syndrome and other rare and debilitating diseases."

Multiple endocrinologists, researchers and centers of excellence are presenting a total of nine abstracts. 

 
Poster Presentations
Thursday, March 5, 2015
1:00pm - 3:00pm
Title   Authors
Medical Treatment of Cushing's Disease with Mifepristone: A Clinical Case Series   Amy M DeGueme, MD
Elizabeth E King, MD
Sasan Mirfakhraee, MD
Mifepristone As a Bridging Therapy to Gamma Knife Radiosurgery in Recurrent Cushing's Disease   Iram Hussain, MD,
Elizabeth E King, MD
Sasan Mirfakhraee, MD
Mifepristone Administration for Preoperative Treatment of Severe Hypercortisolism Associated with Cushing's Disease; A Case Report   Iram Hussain, MD,
Elizabeth E King, MD,
Sasan Mirfakhraee, MD
Mifepristone Treatment Uncovers an Occult Ectopic Parasellar ACTH Tumor: A Case Report   Mostafa Alfishawy,
Alexandria Ajoa Atuahene, MD
Lekha Tummalapalli, MD
Gabrielle Page-Wilson, MD
Sharon L Wardlaw, MD
Kalmon D Post, MD
Eliza B Geer, MD
Mifepristone for the Successful Treatment of Cushing's Syndrome after Multiple Failed Interventions   Mohammad Tufail Ijaz, MD
Neven Pesa, RN, CPNP
Dat Nguyen, PharmD
Glucocorticoid Receptor Blockade with Mifepristone in Patients with Mild Adrenal Hypercortisolism   Aarti Ravikumar, MD
Gillian Mueller Goddard, MD
Eliza B Geer, MD
Alice C Levine, MD
     
Saturday, March 7, 2015
1:00pm - 3:00pm
   
Pre-Surgical Use of Mifepristone for Ectopic Cushing's in a High-Risk Bilateral Adrenalectomy Candidate   Ivy-Joan Madu, MD
Dat Nguyen, PharmD
Treatment of Ectopic Cushing's Syndrome with Mifepristone While Pending Tumor Localization   M Fariba Rahnema, MD
Dolores Chavez, DHA-C, MBA,
M.T., ASCP
Dat Nguyen, PharmD
Marked Improvement in Liver Enzymes During Medical Therapy with Mifepristone for Cushing's Syndrome   Enzo Ragucci, MD
Michele Lamerson, RN, MS, CPNP
     
     

About Korlym®
Korlym competitively blocks the glucocorticoid receptor (GR), one of the two receptors to which cortisol normally binds, thereby inhibiting the effects of excess cortisol in patients with Cushing's syndrome. Since 2012, Corcept has made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym was the first FDA-approved treatment for that illness and the FDA has designated it as an Orphan Drug for that indication.

About Cushing's Syndrome
Endogenous Cushing's syndrome is caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol and is generated by tumors that produce cortisol or ACTH. Cushing's syndrome is an orphan indication that most commonly affects adults aged 20-50. An estimated 10-15 of every one million people are newly diagnosed with this syndrome each year, resulting in over 3,000 new patients annually in the United States. An estimated 20,000 patients in the United States have Cushing's syndrome. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing's syndrome can affect every organ system in the body and can be lethal if not treated effectively.

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company's first FDA-approved medication. The company is conducting a Phase 1/2 trial of mifepristone for the treatment of triple-negative breast cancer, a Phase 1 trial of CORT125134, one of its next-generation selective GR antagonists, and has a portfolio of other proprietary selective GR antagonists that competitively block the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its selective GR antagonists.

Contact Information